Back to Search Start Over

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data

Authors :
Muthuri, Stella G.
Venkatesan, Sudhir
Myles, Puja R.
Leonardi-Bee, Jo
Al Khuwaitir, Tarig S.
Al Mamun, Abdullah
Anovadiya, Ashish P.
Azziz-Baumgartner, Eduardo
Báez, Clarisa
Bassetti, Matteo
Beovic, Bojana
Bertisch, Barbara
Bonmarin, Isabelle
Booy, Robert
Borja-Aburto, Victor H.
Burgmann, Heinz
Cao, Bin
Carratala, Jordi
Denholm, Justin T.
Dominguez, Samuel R.
Duarte, Pericles A.D.
Dubnov-Raz, Gal
Echavarria, Marcela
Fanella, Sergio
Gao, Zhancheng
Gérardin, Patrick
Gianella, Maddalena
Gubbels, Sophie
Herberg, Jethro
Iglesias, Anjarath L. Higuera
Hoger, Peter H.
Hu, Xiaoyun
Islam, Quazi T.
Jiménez, Mirela F.
Kandeel, Amr
Keijzers, Gerben
Khalili, Hossein
Knight, Marian
Kudo, Koichiro
Kusznierz, Gabriela
Kuzman, Iljia
Kwan, Arthur M.C.
Amine, Idriss Lahlou
Langenegger, Eduard
Lankarani, Kamran B
Leo, Yee-Sin
Linko, Rita
Liu, Pei
Madanat, Faris
Mayo-Montero, Elga
McGeer, Allison
Memish, Ziad
Metan, Gokhan
Mickiene, Aukse
Mikić, Dragan
Mohn, Kristin G.
Moradi, Ahmadreza
Nymadawa, Pagbajabyn
Oliva, Maria E.
Oskan, Mehpare
Parekh, Dhruv
Paul, Mical
Polack, Fernando P.
Rath, Barbara A.
Rodríguez, Alejandro H.
Sarrouf, Elena B.
Seale, Anna C.
Sertogullarindan, Bunyamin
Siqueira, Marilda M.
Skręt-Magierło, Joanna
Stephan, Frank
Talarek, Ewa
Tang, Julian W.
To, Kelvin K.
Torres, Antoni
Törün, Selda H.
Tran, Dat
Uyeki, Timothy M.
Van Zwol, Annelies
Vaudry, Wendy
Vidmar, Tjasa
Yokota, Renata T.C.
Zarogoulidis, Paul
Nguyen-Van-Tam, Jonathan
Muthuri, Stella G.
Venkatesan, Sudhir
Myles, Puja R.
Leonardi-Bee, Jo
Al Khuwaitir, Tarig S.
Al Mamun, Abdullah
Anovadiya, Ashish P.
Azziz-Baumgartner, Eduardo
Báez, Clarisa
Bassetti, Matteo
Beovic, Bojana
Bertisch, Barbara
Bonmarin, Isabelle
Booy, Robert
Borja-Aburto, Victor H.
Burgmann, Heinz
Cao, Bin
Carratala, Jordi
Denholm, Justin T.
Dominguez, Samuel R.
Duarte, Pericles A.D.
Dubnov-Raz, Gal
Echavarria, Marcela
Fanella, Sergio
Gao, Zhancheng
Gérardin, Patrick
Gianella, Maddalena
Gubbels, Sophie
Herberg, Jethro
Iglesias, Anjarath L. Higuera
Hoger, Peter H.
Hu, Xiaoyun
Islam, Quazi T.
Jiménez, Mirela F.
Kandeel, Amr
Keijzers, Gerben
Khalili, Hossein
Knight, Marian
Kudo, Koichiro
Kusznierz, Gabriela
Kuzman, Iljia
Kwan, Arthur M.C.
Amine, Idriss Lahlou
Langenegger, Eduard
Lankarani, Kamran B
Leo, Yee-Sin
Linko, Rita
Liu, Pei
Madanat, Faris
Mayo-Montero, Elga
McGeer, Allison
Memish, Ziad
Metan, Gokhan
Mickiene, Aukse
Mikić, Dragan
Mohn, Kristin G.
Moradi, Ahmadreza
Nymadawa, Pagbajabyn
Oliva, Maria E.
Oskan, Mehpare
Parekh, Dhruv
Paul, Mical
Polack, Fernando P.
Rath, Barbara A.
Rodríguez, Alejandro H.
Sarrouf, Elena B.
Seale, Anna C.
Sertogullarindan, Bunyamin
Siqueira, Marilda M.
Skręt-Magierło, Joanna
Stephan, Frank
Talarek, Ewa
Tang, Julian W.
To, Kelvin K.
Torres, Antoni
Törün, Selda H.
Tran, Dat
Uyeki, Timothy M.
Van Zwol, Annelies
Vaudry, Wendy
Vidmar, Tjasa
Yokota, Renata T.C.
Zarogoulidis, Paul
Nguyen-Van-Tam, Jonathan

Abstract

Neuraminidase inhibitors were widely used during the 2009/10 influenza A H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection. We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identified potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling. We included data for 29?234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0·81; 95% CI 0·70?0·93; p=0·0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0·48; 95% CI 0·41?0·56; p<0·0001). Early treatment versus no treatment was also associated with a reduction in mortality (adjusted OR 0·50; 95% CI 0·37?0·67; p<0·0001). These associat

Details

Database :
OAIster
Notes :
doi:10.1016/S2213-2600(14)70041-4
Publication Type :
Electronic Resource
Accession number :
edsoai.on1312864134
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.1016.S2213-2600(14)70041-4